DNTH Stock: Price, Earnings History and SEC Filings
Dianthus Therapeutics, Inc. (DNTH) last traded at $82.38, down 0.39% on the latest session and down 6.4% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.90 against an analyst estimate of $-0.93, a beat of 3.2%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
DNTH earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 4, 2026 | $-0.90 | $-0.93 | +3.23% |
| Mar 2026 | May 5, 2026 | $-0.85 | $-1.17 | +27.35% |
| Dec 2025 | Mar 9, 2026 | $-1.43 | $-0.98 | -45.92% |
| Sep 2025 | Nov 5, 2025 | $-0.97 | $-0.86 | -12.79% |
DNTH beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
How DNTH reacts to earnings
Across its last 8 earnings releases, DNTH moved 5.4% on average the next session, in either direction. It rose after 5 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-04 | After close | +1.90% |
| 2026-05-05 | After close | +0.20% |
| 2026-03-09 | Before open | +21.52% |
| 2026-01-12 | Before open | +2.44% |
| 2025-11-05 | After close | +8.00% |
| 2025-10-16 | Before open | -0.55% |
| 2025-08-07 | After close | -2.04% |
| 2025-05-12 | After close | -6.18% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
DNTH financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $2M | -$162M | – | -7973.3% | $-4.20 |
| 2024 | $6M | -$85M | – | -1362.8% | $-2.55 |
| 2023 | $3M | -$44M | – | -1541.2% | $-8.45 |
| 2019 | $0 | -$77M | -$60M | – | – |
| 2018 | $0 | -$58M | -$50M | – | – |
| 2017 | $0 | -$35M | -$24M | – | – |
| 2016 | $0 | -$9M | -$7M | – | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for DNTH
- 10-Q · Aug 4, 2026
- 8-K · Aug 4, 2026Results of operations, Financial statements and exhibits
- 8-K · Jun 12, 2026Other events, Financial statements and exhibits
- 8-K · May 22, 2026Shareholder vote
- 10-Q · May 5, 2026
- 8-K · May 5, 2026Results of operations, Financial statements and exhibits
- DEF 14A · Apr 9, 2026
- 8-K · Mar 26, 2026Other events, Financial statements and exhibits
- 8-K · Mar 12, 2026Material agreement, Financial statements and exhibits
- 424B5 · Mar 11, 2026
Insider filing activity
DNTH insiders filed 8 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
DNTH news
- Regeneron (REGN) Q3 Earnings and Revenues Beat EstimatesOct 30, 2026 · finance.yahoo.com
- Halozyme Therapeutics (HALO) Reports Next Week: Wall Street Expects Earnings GrowthOct 29, 2026 · finance.yahoo.com
- Dianthus Therapeutics (DNTH) Stock May Be Above Fair Value Following Its 5x RunOct 20, 2026 · finance.yahoo.com
About Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc. (DNTH) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.